CTB-1550

CTB-1550 is a small molecule pharmacological chaperone developed by Cantabio Pharmaceuticals for the treatment of Parkinson's disease. It is designed to target and stabilize the DJ-1 protein (also known as PARK7), a multifunctional protein that plays a critical role in protecting neurons from oxidative stress and preventing the misfolding and aggregation of proteins such as alpha-synuclein. In Parkinson's disease, the loss of DJ-1 function or its destabilization contributes to neurodegeneration. CTB-1550 binds to DJ-1 to maintain its native, active conformation, thereby restoring its neuroprotective capabilities. This approach represents a potential disease-modifying therapy aimed at slowing or halting the progression of Parkinson's disease by addressing the underlying biochemical triggers of neuronal death.

Other names

DJ-1 chaperoneDJ1 chaperoneDJ 1 chaperoneDJ-1 stabilizerDJ1 stabilizerDJ 1 stabilizer